360 MD Austin
Austin, TX
Physician credentials on file
§ — Substance profile
Egrifta · Growth-hormone-releasing hormone analogue
01 — Regulatory status
Regulatory status · United States · as of October 2026
FDA-approved (Egrifta) for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. Use for any other purpose is off-label.
Source: FDA 503A Bulks List · PCAC meeting records · verified October 2026
Reviewed October 2026 · Sources: FDA, EMA
02 — Researched for
Visceral fat reduction in HIV lipodystrophy; NAFLD; cognitive function in older adults.
03 — What the evidence shows
Phase 3 trials showed roughly 15–18% visceral fat reduction in the approved population. A NIH-funded trial found modest cognitive effects in older adults; not replicated at scale.
04 — What is claimed but not shown
Visceral fat loss in healthy adults without lipodystrophy; general anti-aging benefit.
05 — Known risks
Glucose intolerance, fluid retention, arthralgia; contraindicated in active malignancy; effect reverses on discontinuation.
06 — Researched for these goals
07 — Questions for your physician
Every practice in the registry that lists peptide therapy, sorted by distance and nothing else. You contact the practice directly.
Austin, TX
Physician credentials on file
La Jolla, CA
No physician listed on the practice website
Chandler, AZ
Physician credentials on file
Alpharetta, GA
Physician credentials on file
San Francisco, CA
Ahvie Herskowitz, MD · Ann Lee, MD
Steamboat Springs, CO
Physician credentials on file
Listed for transparency, not as an endorsement of any practice, substance or protocol. Most peptides are not FDA-approved for the uses they are offered for.
Reviewed October 2026 · Sources: FDA, EMA
This page reports on the state of research and regulation for orientation. It is not medical advice, not a recommendation for or against any substance, and not an offer. Regulatory status changes; the date shown is the date of our last verification. Discuss any treatment with a licensed physician.